Metastatic renal cell carcinoma of unknown primary site. Clinical follow-up
- 作者: Ognerubov N.1,2, Antipova T.3, Gumareva G.4
-
隶属关系:
- Derzhavin Tambov State University
- Tambov Regional Oncological Clinical Dispensary
- PET-Technology
- Pathological Bureau
- 期: 卷 22, 编号 3 (2020)
- 页面: 149-153
- 栏目: Clinical Case
- URL: https://journals.rcsi.science/1815-1434/article/view/52652
- DOI: https://doi.org/10.26442/18151434.2020.3.200301
- ID: 52652
如何引用文章
全文:
详细
Renal cell cancer metastases without evidence of a primary tumor are extremely rare. These variants are usually showed as a spontaneous description of single clinical cases.
Aim. This contribution is a clinical follow-up of synchronous renal cell cancer metastases of unknown primary site.
Results. A 52-year-old patient U. with a history of increased blood pressure, up to 170/100 mmHg for the last 5 years, who had undergone many instrumental examinations, including ultrasound examination, because of this disease. The computed tomography of the abdomen showed a 49×75 mm heterogeneous tumor in the right adrenal gland in October 2017. The combined positron emission and X-ray computed tomography showed a 79×54×41 mm mass in the right adrenal gland, associated with elevated fluorodeoxyglucose metabolic activity SUVmax 7.25. Focal accumulation of the radiopharmaceutical SUVmax 4.31 in a 17×11×24 mm mass was detected in the space of bifurcation in the mediastinum. The lytic lesion (10×15 mm) was found in right superior L3 articular process. The patient underwent retroperitoneoscopic adrenalectomy and thoracoscopic removal of mediastinal tumor in November 2017 because of the oligometastatic nature of the process. The histological study identified clear-cell carcinoma with areas of papillary structure in the right adrenal gland. The immunohistochemical study showed carcinoma cells intensively expressing CD10, and some other cells – RCC. The immune phenotype of the tumor was identified as clear-cell renal cell carcinoma. The immunohistological and immunohistochemical analysis reviled the metastases of the same variant of renal cell carcinoma in one of 9 lymph nodes. The patient was treated with pazopanib. The primary renal tumor was not detected during the dynamic observation, including the application of annual combined positron emission and X-ray computed tomography. The patient is alive without disease progression with a follow-up of 32 months.
Conclusion. Metastases of clear-cell renal cell carcinoma, including adrenal gland, without evidence of a primary site are extremely rare. The main method of treatment is a combination of surgery and targeted therapy, providing long-term local control of the course of the disease.
作者简介
N. Ognerubov
Derzhavin Tambov State University; Tambov Regional Oncological Clinical Dispensary
编辑信件的主要联系方式.
Email: ognerubov_n.a@mail.ru
ORCID iD: 0000-0003-4045-1247
俄罗斯联邦, Tambov
T. Antipova
PET-Technology
Email: antipovats@gmail.com
ORCID iD: 0000-0003-4165-8397
doctor, PET-Technology
俄罗斯联邦, TambovG. Gumareva
Pathological Bureau
Email: ognerubov_n.a@mail.ru
doctor, Pathological Bureau
俄罗斯联邦, Tambov参考
- Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986; 136: 376–9. doi: 10.1016/s0022-5347(17)44873-7
- Bianchi M, Sun M, Jeldres C et al. Distribution of metastatic sites in renal cell carcinoma: a population based analysis. Ann Oncol 2012; 23 (4): 973–80. doi: 10.1093/annonc/mdr362
- Kane CJ, Mallin K, Ritchey J et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008; 113 (1): 78–83. doi: 10.1002/cncr.23518
- Handorf CR, Kulkarni A, Grenert JP et al. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol 2013; 37: 1067–75. doi: 10.1097/PAS.0b013e31828309c4
- Özturk H. Bilateral synchronous adrenal metastases of renal cell carcinoma: a case report and review of the literature. Oncol Lett 2015; 9: 1897–901. doi: 10.3892/ol.2015.2915
- Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611–23. doi: 10.1016/S0022-5347(05)65640-6
- Golimbu M, Joshi P, Sperber A et al. Renal cell carcinoma: survival and prognostic factors. Urology 1986; 27: 291–301. doi: 10.1016/0090-4295(86)90300-6
- Bhatia S, Ng S, Hodder SC Metastatic cutaneous head and neck renal cell carcinoma with no known primary: case report. Br J Oral Maxillofac Surg 2010; 48: 214–5. doi: 10.1016/j.bjoms.2009.11.012
- Wei EY, Chen YB, Hsieh JJ Genomic characterisation of two cancers of unknown primary cases supports a kidney cancer origin. BMJ Case Rep 2015. doi: 10.1136/bcr-2015-212685
- Costantino C, Thomas GV, Ryan C et al. Metastatic renal cell carcinoma without evidence of a renal primary. Int Urol Nephrol 2016; 48 (1): 73–7. doi: 10.1007/s11255-015-1145-3
- Fayaz MS, Al-Qaderi AE, El-Sherify MS Metastatic renal cell carcinoma with undetectable renal mass presenting as lymphadenopathy. CEN Case Rep 2017; 6 (1): 36–8. doi: 10.1007/s13730-016-0239-9
- Heary RF, Agarwal N, Barrese JC et al. Metastatic renal cell carcinoma, with a radiographically occult primary tumor, presenting in the operative site of a thoracic meningioma: long-term follow-up. Case report. J Neurosurg Spine 2014; 21 (4): 628–33. doi: 10.3171/2014.6.SPINE13448
- Woodhouse L, Watkins J, Navalkissoor S, Gillmore R Metastatic bone disease from an occult renal primary. BMJ Case Rep 2019; 12 (4): e227657. doi: 10.1136/bcr-2018-227657
- Johnson MT, Bahnson RR Zynger, DL Metastatic clear cell renal cell carcinoma to the adrenal gland without an identifiable primary tumor. Int J Urol 2012; 19: 92–3. doi: 10.1111/j.1442-2042.2011.02904.x
- Cancer today. In: GLOBOCAN 2018. https://gco.iarc.fr/today/data/factsheets/cancers/34-Non-hodgkin-lymphoma-fact-sheet.pdf.
- Kumar RM, Aziz T, Jamshaid H et al. Metastatic renal cell carcinoma without evidence of a primary renal tumour. Curr Oncol 2014; 21 (3): e521–e54. doi: 10.3747/co.21.1914
- Choi YR, Han HS, Lee OJ et al. Metastatic Renal Cell Carcinoma in a Supraclavicular Lymph Node with No Known Primary: A Case Report. Cancer Res Treat 2012; 44 (3): 215–8. doi: 10.4143/crt.2012.44.3.215
- Walton J, Li J, Clifton MM et al. Metastatic clear cell renal cell carcinoma to the forearm without identifiable primary renal mass. Urol Case Rep 2019; 27: 100989. doi: 10.1016/j.eucr.2019.100989
- Kawakita M, Kawamura J, Hida S et al. Renal cell carcinoma, primary lesion which was not easily identified: report of two cases. Hinyokika Kiyo 1985; 31 (3): 463–73. PMID: 4025083
- Wayne M, Wang W, Bratcher J et al. Renal cell cancer without a renal primary. World J Surg Oncol 2010; 8: 18. doi: 10.1186/1477-7819-8-18
- Abdou AG, Kandil M, Elshakhs S et al. Renal Cell Carcinoma With Rhabdoid and Sarcomatoid Features Presented as a Metastatic Thigh Mass With an Unusual Immunohistochemical Profile. Rare Tumors 2014; 6 (1): 5037. doi: 10.4081/rt.2014.5037
- Higuchi T, Yamamoto N, Hayashi K Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma. Bone Joint Lett J 2018; 100-B: 1241–8. doi: 10.1302/0301-620X.100B9.BJJ-2017-1163.R3
- Marcus PB, Kemp CB Ectopic renal cell carcinoma: pathologist’s problem. Urology 1978; 1978 (12): 453–7. doi: 10.1016/0090-4295(78)90303-5
- Terada T Extra-renal clear cell renal cell carcinoma probably arising from mesodermal embryonic remnants. Pathol Int 2012; 62: 291–3. doi: 10.1111/j.1440-1827.2011.02780.x
- Sorscher SM, Greco FA Papillary Renal Carcinoma Presenting as a Cancer of Unknown Primary (CUP) and Diagnosed through Gene Expression Profiling. Case Rep Oncol 2012; 5 (2): 229–32. doi: 10.1159/000339130
- Overby A, Duval L, Ladekarl M et al. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature. Clin Genitourin Cancer 2019; 17 (1): e32–e37. doi: 10.1016/j.clgc.2018.08.005
- Lombardo R, Tosi F, Nocerino A et al. The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. Front Oncol 2020; 10: 533. doi: 10.3389/fonc.2020.00533